VRTX34.SA Vertex Pharmaceuticals Incorporated

Healthcare Biotechnology Sao Paulo Exchange
93.40 BRL
Close of Nov 5, 2026
65.18 97.20
Market cap
BRL 758B
P/E
36.9x
P/B
6.74x
ROE
17.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is VRTX34.SA undervalued?

Graham number

The Graham number of Vertex Pharmaceuticals Incorporated cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Vertex Pharmaceuticals Incorporated fundamental analysis

No fundamental analysis for Vertex Pharmaceuticals Incorporated yet.

Vertex Pharmaceuticals Incorporated stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for …

Full company profile